Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Eur Neuropsychopharmacol. 2012 Nov 21;23(8):852–864. doi: 10.1016/j.euroneuro.2012.10.006

Fig. 5.

Fig. 5

(A) [3H]Ketanserin specific binding (2 nM) displacement curves by DOI in postmortem frontal cortex of antipsychotic-free (AP-F) schizophrenic subjects and controls. (B) [3H]Ketanserin specific binding (2 nM) displacement curves by DOI in postmortem frontal cortex of antipsychotic-treated (AP-T) schizophrenic subjects and controls. (C) Fraction of high-affinity sites of DOI displacing [3H]ketanserin specific binding. (D) Normalized high-affinity (log Ki-high) of DOI displacing [3H]ketanserin specific binding in schizophrenic subjects and individually matched controls. *p<0.05; ***p<0.001; n.s., not significant; Student’s t-test. See Supplementary Tables 1 and 2 for demographic information. See Table 1 for statistical analysis. All values represent means±SEM.